Nuvama has reiterated its ‘Buy’ rating on Dr Lal PathLabs and raised the target price to Rs 2,140 from Rs 1,900, implying a potential upside of 21% from the current market price of Rs 1,756.
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.